Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients

Breast Cancer Research and Treatment

Volumn 98, Issue 2, 2006, Pages 179-184

  Solomayer, Erich F ^a   Becker, Sven ^a   Pergola Becker, Graziella ^a   Bachmann, Robert ^a   Krämer, Bernhard ^a   Vogel, Ulrich ^b   Neubauer, Hans ^a   Wallwiener, Diethelm ^a   Huober, Jens ^a   Fehm, Tanja N ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bone marrow; Breast cancer; Disseminated tumor cells; Double immunofluorescence; HER2

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TUMOR; TUMOR CELL;

ADULT; AGED; BONE MARROW; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 33745903909     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9147-y     Document Type: Article

References (29)

1. Solomayer EF, Diel IJ, Salanti G, Hahn M, Gollan C, Schutz F, Bastert G: Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 7: 4102-4108, 2001
2. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525-533, 2000
3. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19: 3669-3674, 2001
4. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18: 80-86, 2000
5. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K: The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103: 884-891, 2004
6. Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL: Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5: 3999-4004, 1999
7. Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 84: 8672-8676, 1987
8. Slamon DJ, Goldolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/proto-oncogene in human breast cancer and ovarian cancer. Science 244: 707-712, 1989
9. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994
10. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58(13): 2825-2831, 1998
11. Weiner LM: Monoclonal antibody therapy of cancer. Semin Oncol 26(5 Suppl 14): 43-51, 1999
12. Piccart-Gebhart MJ: First results of the HERA trial. Session 'Advances in Monoclonal Antibody Therapy for Breast Cancer' (Scientific Symposium), ASCO-Meeting, 13-17 May 2005, Orlando, Florida
13. Di Leo A, Dowsett M, Horten B, Penault-Llorca F: Current status of HER2 testing. Oncology 63: 25-32, 2003
14. Edgerton SM, Moore D 2nd, Merkel D, Thor AD: erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 11: 214-221, 2003
15. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036-1043, 2003
16. Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF: HER2 expression on disseminated tumor cells from bone marrow of breast cancer patients. Anticancer Res 25: 2171-2176, 2005
17. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B: Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10: 5342-5348, 2004
18. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10: 8152-8162, 2004
19. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K: Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11: 3678-3685, 2005
20. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G: Differential expression of proliferated - associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85: 1419-1423, 1993
21. Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002
22. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999
23. Romond E: Joint analysis of NSABP-B-31 and NCCTG-N9831; Session 'Advances in Monoclonal Antibody Therapy for Breast Cancer' (Scientific Symposium), ASCO-Meeting, 13-17 May 2005, Orlando, Florida
24. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K: ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61: 1890-1895, 2001
25. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101: 9393-9398, 2004
26. Tanner M, Jarvinen P, Isola J: Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer. Cancer Res 61: 5345-5348, 2001
27. Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G, Zanker KS: Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer 76: 824-828, 1998
28. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Naughton M, Norton L, Winer E, Hudis C: CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22(14S): 512, 2004
29. Hayes DF, Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C, Doyle GV, Terstappen LW: Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 21: 1111-1117, 2002